Company Profiles

driven by the PitchBook Platform

Arvinas

Description

Developer of protein degradation therapeutics created to degrade and destroy disease-causing proteins via the body's own protein disposal system. The company's protein degradation therapeutics are formed by developing small-molecule strategies aimed at removing unwanted cellular proteins, enabling healthcare professionals treat cancer, pro-inflammatory, autoimmune disorders and rare diseases by eliminate disease-causing proteins from the body.

2013

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$41.6M

Latest Deal Amount

$62.4M

Total Amount Raised

Description

Developer of protein degradation therapeutics created to degrade and destroy disease-causing proteins via the body's own protein disposal system. The company's protein degradation therapeutics are formed by developing small-molecule strategies aimed at removing unwanted cellular proteins, enabling healthcare professionals treat cancer, pro-inflammatory, autoimmune disorders and rare diseases by eliminate disease-causing proteins from the body.

Website:

www.arvinas.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

5 Science Park 395 Winchester Avenue New Haven, CT 06511United States +1 (203) 535-1456
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Arvinas's full profile, request a free trial.

Arvinas Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Arvinas Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Arvinas Investors (8)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
5AM VenturesVenture CapitalMinority000 0000000 0000
Canaan PartnersVenture CapitalMinority000 0000000 0000
Connecticut InnovationsVenture CapitalMinority000 0000000 0000
Elm Street VenturesPE/BuyoutMinority000 0000000 0000
New Leaf Venture PartnersVenture CapitalMinority000 0000000 0000
5AM Ventures Venture Capital
Canaan Partners Venture Capital
Connecticut Innovations Venture Capital
Elm Street Ventures PE/Buyout
New Leaf Venture Partners Venture Capital

Arvinas Executive Team (13)

NameTitleBoard
Seat
Contact
Info
John HoustonPresident of R&D & Chief Scientific Officer
Sean CassidyChief Financial Officer
Robert Kleinfield Ph.DChief Development Officer
Jim Winkler Ph.DChief Scientific Officer
Craig Crews Ph.DFounder & Chief Scientific Advisor
John Houston President of R&D & Chief Scientific Officer
Sean Cassidy Chief Financial Officer
Robert Kleinfield Ph.D Chief Development Officer
Jim Winkler Ph.D Chief Scientific Officer
Craig Crews Ph.D Founder & Chief Scientific Advisor

Arvinas Board Members (7)

NameRepresentingRoleSinceContact
Info
Andrew Levin Ph.DRA Capital ManagementManaging Director000 0000
Bradley MargusSelfBoard Member000 0000
Jonathan Soderstrom Ph.DSelfBoard Member000 0000
Kush Parmar Ph.D5AM VenturesManaging Partner000 0000
Liam Ratcliffe Ph.DNew Leaf Venture PartnersManaging Director & General Partner000 0000
Andrew Levin Ph.D Managing Director RA Capital Management
Bradley Margus Board Member Self
Jonathan Soderstrom Ph.D Board Member Self
Kush Parmar Ph.D Managing Partner 5AM Ventures
Liam Ratcliffe Ph.D Managing Director & General Partner New Leaf Venture Partners
Request full access to PitchBook